Tingting Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tingting Fang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Genqing Zhou
Department of Cardiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publications - Jiaqi Shen
Quyang Community Health Service Center of Hongkou District, Shanghai 200437, China
2 shared publications - Linqun Zheng
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications - Mei Kang
Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications - Qitong Zhang
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2 shared publications - Shaowen Liu
Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 606
Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
- 17 November 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 606
Open AccessMenstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
- Open Access
- 23 October 2026
- Published by MDPI AG in Preprints.org
Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.
- 23 October 2026
- Published by MDPI AG in Preprints.org
Open AccessMenstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.
- 8 September 2021
- Published by IMR Press in The Heart Surgery Forum
- Vol. 24 (5) , E887-E892
Peripheral Artery Disease on The Prognosis Value of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Retrospective, Single-Center Cohort Study
Objective: The purpose of this investigation aimed to clarify the impact of peripheral artery disease (PAD) on the prognosis value of patients with stable coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI). Methods: The SPSS 16 software was used for secondary analysis of DRYAD database data. A total of 204 patients were enrolled from Shinonoi General Hospital for newly diagnosed stable CAD and received PCI performance between October 2014 and October 2017. Patients with old myocardial infarction (MI) were excluded. We divided patients into two groups with PAD and without PAD. The primary endpoints were major adverse cardiac events (MACE, defined as all-cause death, non-fatal MI, and non-fatal stroke) and cardiovascular events (defined as cardiovascular death, non-fatal MI, and non-fatal stroke). The secondary outcomes were the individual components of the composite primary outcomes. The median follow-up time was 783 days. Results: No statistical difference was found between PAD and non-PAD patients of lesional characteristics. Spearman’s rank correlations indicate diabetes mellitus (DM) (P = 0.019) and HbA1c (P = 0.009) are positively correlated with PAD. In Kaplan-Meier analysis, patients with PAD predicted poor prognosis in MACE (P < 0.05) and cardiovascular events (P < 0.05). In Multivariable Cox proportional hazards analysis, patients with PAD independently predicted MACE and cardiovascular events. Conclusions: PAD is a significant mediator for the prognosis of patients with stable CAD who underwent PCI treatment.
- 8 September 2021
- Published by IMR Press in The Heart Surgery Forum
- Vol. 24 (5) , E887-E892
Peripheral Artery Disease on The Prognosis Value of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Retrospective, Single-Center Cohort Study
Objective: The purpose of this investigation aimed to clarify the impact of peripheral artery disease (PAD) on the prognosis value of patients with stable coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI). Methods: The SPSS 16 software was used for secondary analysis of DRYAD database data. A total of 204 patients were enrolled from Shinonoi General Hospital for newly diagnosed stable CAD and received PCI performance between October 2014 and October 2017. Patients with old myocardial infarction (MI) were excluded. We divided patients into two groups with PAD and without PAD. The primary endpoints were major adverse cardiac events (MACE, defined as all-cause death, non-fatal MI, and non-fatal stroke) and cardiovascular events (defined as cardiovascular death, non-fatal MI, and non-fatal stroke). The secondary outcomes were the individual components of the composite primary outcomes. The median follow-up time was 783 days. Results: No statistical difference was found between PAD and non-PAD patients of lesional characteristics. Spearman’s rank correlations indicate diabetes mellitus (DM) (P = 0.019) and HbA1c (P = 0.009) are positively correlated with PAD. In Kaplan-Meier analysis, patients with PAD predicted poor prognosis in MACE (P < 0.05) and cardiovascular events (P < 0.05). In Multivariable Cox proportional hazards analysis, patients with PAD independently predicted MACE and cardiovascular events. Conclusions: PAD is a significant mediator for the prognosis of patients with stable CAD who underwent PCI treatment.
- Open Access
- 28 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (15) , 3339
The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy
Background: The cardiac Magnetic Resonance Imaging (MRI) characteristics of rare diseases with the hypertrophic cardiomyopathy (HCM) phenotype are not well defined. Methods: Seventy-three sequential patients and 34 of their relatives, who have the HCM phenotype, were included. All subjects underwent cardiac MRI and genetic testing. Results: Of these 107 patients with phenotypic HCM, seven rare diseases were identified: four cases with LAMP2, one case with PRKAG2, one case with TTR mutation, and one case with senile systemic amyloidosis. Subjects with rare diseases had diffuse LGE, and the percentage of those with LGE was significantly higher than that of other HCM (median: 18.9%, interquartile range (IQR): 14.05 to 28.2% versus 7.8%, IQR: 4.41 to 14.56%; p = 0.003). Additionally, global T1 and ECV were significantly higher in subjects with rare diseases (global T1: 1423.1 ± 93.3 ms versus 1296.2 ± 66.6 ms; global ECV: 44.3 ± 11.5% versus 29.9 ± 4.5%; all p < 0.001). Conclusions: Cardiac MRI suggests the existence of distinct imaging characteristics, including via LGE and T1 mapping, among rare diseases that mimic HCM and HCM itself.
- 28 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (15) , 3339
Open AccessThe Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy
Background: The cardiac Magnetic Resonance Imaging (MRI) characteristics of rare diseases with the hypertrophic cardiomyopathy (HCM) phenotype are not well defined. Methods: Seventy-three sequential patients and 34 of their relatives, who have the HCM phenotype, were included. All subjects underwent cardiac MRI and genetic testing. Results: Of these 107 patients with phenotypic HCM, seven rare diseases were identified: four cases with LAMP2, one case with PRKAG2, one case with TTR mutation, and one case with senile systemic amyloidosis. Subjects with rare diseases had diffuse LGE, and the percentage of those with LGE was significantly higher than that of other HCM (median: 18.9%, interquartile range (IQR): 14.05 to 28.2% versus 7.8%, IQR: 4.41 to 14.56%; p = 0.003). Additionally, global T1 and ECV were significantly higher in subjects with rare diseases (global T1: 1423.1 ± 93.3 ms versus 1296.2 ± 66.6 ms; global ECV: 44.3 ± 11.5% versus 29.9 ± 4.5%; all p < 0.001). Conclusions: Cardiac MRI suggests the existence of distinct imaging characteristics, including via LGE and T1 mapping, among rare diseases that mimic HCM and HCM itself.
- 3 March 2021
- Published by IMR Press in The Heart Surgery Forum
- Vol. 24 (2) , E209-E214
Tricuspid Valve Replacement: Mechanical or Biological Prostheses? A Systematic Review and Meta-Analysis
Background: Tricuspid valve replacement (TVR) is seldom performed in cardiac valve surgery, and there currently are no clinical guidelines as to which type of prostheses is better in tricuspid valve position. This meta-analysis was performed to compare the results of mechanical and biological prostheses for TVR. Methods: We searched the Pubmed, Cochrane, and Embase clinical trial databases to collect all related studies published from January 1, 2000 to July 31, 2020. A random-effects model was used to evaluate the odds ratios (OR) and its 95% confidence intervals (CI) of time-to-event related effects of the surgical procedures; every study’s quality was evaluated by the Newcastle-Ottawa Scale (NOS). Results: A total of 13 retrospective studies, including 1453 patients were analyzed. There were no statistically differences between mechanical and biological prostheses with respect to prosthetic valve failure [OR = 0.84, 95% CI(0.54, 1.28), P = .41], bleeding [OR = 0.84, 95% CI(0.54,1.28), P = .41], reoperation [OR = 1.02, 95% CI(0.58,1.78), P = .95], early mortality [OR = 1.35, 95% CI(0.82,2.25), P = .24] and long-time survival [OR = 1.09, 95% CI(0.70, 1.69), P = .70], but a significant difference can be seen in mechanical prostheses with a higher risk of thrombosis [OR = 0.17, 95% CI(0.05, 0.60), P = .006, I2 = 0%]. Conclusions: In tricuspid valve position, mechanical valve prostheses have a higher risk of thrombosis than biological prostheses, but no statistical differences between mechanical and biological prostheses with respect to prosthetic valve failure, bleeding, reoperation, early mortality, and long-term survival. The valve disease and patient’s age and risk factors are the most important considerations in the decision-making process. The more specific conclusion needs to be further proved by large-sample, multi-center, randomized, double-blind and control trials.
- 3 March 2021
- Published by IMR Press in The Heart Surgery Forum
- Vol. 24 (2) , E209-E214
Tricuspid Valve Replacement: Mechanical or Biological Prostheses? A Systematic Review and Meta-Analysis
Background: Tricuspid valve replacement (TVR) is seldom performed in cardiac valve surgery, and there currently are no clinical guidelines as to which type of prostheses is better in tricuspid valve position. This meta-analysis was performed to compare the results of mechanical and biological prostheses for TVR. Methods: We searched the Pubmed, Cochrane, and Embase clinical trial databases to collect all related studies published from January 1, 2000 to July 31, 2020. A random-effects model was used to evaluate the odds ratios (OR) and its 95% confidence intervals (CI) of time-to-event related effects of the surgical procedures; every study’s quality was evaluated by the Newcastle-Ottawa Scale (NOS). Results: A total of 13 retrospective studies, including 1453 patients were analyzed. There were no statistically differences between mechanical and biological prostheses with respect to prosthetic valve failure [OR = 0.84, 95% CI(0.54, 1.28), P = .41], bleeding [OR = 0.84, 95% CI(0.54,1.28), P = .41], reoperation [OR = 1.02, 95% CI(0.58,1.78), P = .95], early mortality [OR = 1.35, 95% CI(0.82,2.25), P = .24] and long-time survival [OR = 1.09, 95% CI(0.70, 1.69), P = .70], but a significant difference can be seen in mechanical prostheses with a higher risk of thrombosis [OR = 0.17, 95% CI(0.05, 0.60), P = .006, I2 = 0%]. Conclusions: In tricuspid valve position, mechanical valve prostheses have a higher risk of thrombosis than biological prostheses, but no statistical differences between mechanical and biological prostheses with respect to prosthetic valve failure, bleeding, reoperation, early mortality, and long-term survival. The valve disease and patient’s age and risk factors are the most important considerations in the decision-making process. The more specific conclusion needs to be further proved by large-sample, multi-center, randomized, double-blind and control trials.
- 22 May 2019
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 35 (6) , 493-502
Mitochondrial dysfunction and chronic lung disease
The functions of body gradually decrease as the age increases, leading to a higher frequency of incidence of age-related diseases. Diseases associated with aging in the respiratory system include chronic obstructive pulmonary disease (COPD), IPF (idiopathic pulmonary fibrosis), asthma, lung cancer, and so on. The mitochondrial dysfunction is not only a sign of aging, but also is a disease trigger. This article aims to explain mitochondrial dysfunction as an aging marker, and its role in aging diseases of lung. We also discuss whether the mitochondria can be used as a target for the treatment of aging lung disease.
- 22 May 2019
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 35 (6) , 493-502
Mitochondrial dysfunction and chronic lung disease
The functions of body gradually decrease as the age increases, leading to a higher frequency of incidence of age-related diseases. Diseases associated with aging in the respiratory system include chronic obstructive pulmonary disease (COPD), IPF (idiopathic pulmonary fibrosis), asthma, lung cancer, and so on. The mitochondrial dysfunction is not only a sign of aging, but also is a disease trigger. This article aims to explain mitochondrial dysfunction as an aging marker, and its role in aging diseases of lung. We also discuss whether the mitochondria can be used as a target for the treatment of aging lung disease.